News

Drug developers deeply concerned
Enlarge image

PolicyEUUK

Drug developers deeply concerned

28.11.2013 - EU industry associations urge EU legislators: Don’t make the regulatory process too long, putting Europe’s competitiveness at risk.

Just before Christmas, the European Commission, European Parliament and the EU Council are expected to finalise the Clinical Trials Regulation. However, drug developers and manufacturers are deeply concerned. They believe that the  compromise could fail to meet the original goal of the Regulation which was to reverse decreasing numbers of clinical trials carried out in the bloc.

In a joint statement EuropaBio, the European Federation of Pharma Industry Associations (EFPIA), the Association of Clinical Research Organisations (ACRO), Cancer Research UK, and the Patients Network for Medical Research and Health (EGAN) have urged the legislators not to dilute the original aim of the regulation:  "It is imperative to build on Europe’s innovative edge – not just for competitive reasons, but because innovation is the tool needed to deliver new and improved medicines to patients,“ they stress.  "The longer the regulatory process takes to approve a clinical trial, or process regulatory procedures around it, the greater the cost of the trial. Higher costs can result in fewer trials being run, reducing our ability to understand treatments better. Towards this end, we strongly support the path set out by the Commission as well as the European Parliament in ensuring competitive timelines for these authorisations, and urges the Council to support this approach moving forward.“

The associations say it is essential to ensure that timelines are predictable and are in no case longer than the timelines already established in the current Directive. The proposal of the Commission initially intended to shorten the Clinical Trial Authorisation Timeline from 60 days (90 days for advanced therapy medicinal products such as gene and cell therapies) to 25 days (plus 5 extra days for ATMPs). However as there are member states where the timeline is significantly longer, industry fears that the Council will prolong the timeline. According to EuropaBio "everything going beyond 60 days would clearly be uncompetitive and send the wrong signal“. 

Short timelines at high quality level, however, are possible. In the UK, the initial assessment is performed within 30 days, according to the MHRA. Applications for Healthy Volunteer Trials and sponsor-determined Phase I trials in non-oncology patients will be assessed and processed within 30 days, with an average of 14 days or less.

eurobiotechnews.eu/tg

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK73.5%
  • WILEX (D)0.81 EUR42.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • IMMUNICUM AB (S)16.40 SEK-36.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6174.4%
  • IXICO (UK)66.50 GBP737.5%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014